iShares TIPS Bond ETF (TIP)
- Previous Close
105.89 - Open
105.73 - Bid 105.30 x 1300
- Ask 105.89 x 4000
- Day's Range
105.51 - 105.77 - 52 Week Range
101.74 - 110.48 - Volume
1,946,423 - Avg. Volume
2,229,937 - Net Assets 18.81B
- NAV 105.62
- PE Ratio (TTM) 11.87
- Yield 2.74%
- YTD Daily Total Return -1.63%
- Beta (5Y Monthly) 0.84
- Expense Ratio (net) 0.19%
The index tracks the performance of inflation-protected public obligations of the U.S. Treasury, commonly known as “TIPS,” that have a remaining maturity of more than one year. The fund will invest at least 80% of its assets in the component securities of the index, and it will invest at least 90% of its assets in U.S. Treasury securities that BFA believes will help the fund track the index.
iShares
Fund Family
Inflation-Protected Bond
Fund Category
18.81B
Net Assets
2003-12-04
Inception Date
Performance Overview: TIP
Trailing returns as of 4/24/2024. Category is Inflation-Protected Bond.
People Also Watch
Recent News: TIP
Research Reports: TIP
Analyst Report: Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
RatingPrice TargetAEM: What does Argus have to say about AEM?
AGNICO EAGLE MINES LTD has an Investment Rating of SELL; a target price of $53.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetAnalyst Report: The Goldman Sachs Group, Inc.
Goldman Sachs is a leading global investment banking and asset management firm. Approximately 20% of its revenue comes from investment banking, 45% from trading, 20% from asset management and 15% from wealth management and retail financial services. Around 60% of the company's net revenue is generated in the Americas, 15% in Asia, and 25% in Europe, the Middle East, and Africa.
RatingPrice TargetAnalyst Report: The Walt Disney Company
Walt Disney owns the rights to some of the most globally recognized characters, from Mickey Mouse to Luke Skywalker. These characters and others are featured in several Disney theme parks around the world. Disney makes live-action and animated films under studios such as Pixar, Marvel, and Lucasfilm and also operates media networks including ESPN and several TV production studios. Disney shifted into a more streaming-focused firm by acquiring the remainder of Hulu and launching Disney+ and ESPN+. Across its streaming platforms, Disney had over 235 million subscribers as of September 2022, up sharply from under 64 million in December 2019.
RatingPrice Target